Browsing by Author Kim W.S.
Showing results 1 to 9 of 9
| Preview | Issue Date | Title | Author(s) |
|---|---|---|---|
| 5-Jan-2022 | A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. | Budde E.; Gopal A.K.; Kim W.S.; Flinn I.W.; Cheah C.Y.Y.; Nastoupil L.; Matasar M.J.; Diefenbach C.S.; Gregory G.P.; Qazi I.; Pang C.-F.; Leabman M.; Hernandez G.; Sison I.; Keyt B.A.; Chen D.; Armand P. | |
| 14-Jan-2025 | A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas. | Kim W.S.; Shortt J. ; Zinzani P.L.; Mikhailova N.; Radeski D.; Ribrag V.; Domenech E.D.; Sawas A.; Alexis K.; Emig M.; Elbadri R.; Hajela P.; Ravenstijn P.; Pinto S.; Garcia L.; Overesch A.; Pietzko K.; Horwitz S. | |
| 30-Aug-2021 | IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial. | Assouline S.; Kim W.S.; Sehn L.H.; Schuster S.J.; Cheah C.Y.; Nastoupil L.J.; Shadman M.; Yoon S.-S.; Matasar M.J.; Diefenbach C.; Gregory G.P.; Bartlett N.L.; Wei M.C.; Doral M.Y.; Yin S.; Negricea R.; Li C.-C.; Penuel E.; Huang H.; Budde L.E. | |
| 11-Jan-2024 | Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. | Matasar M.; Bartlett N.L.; Shadman M.; Budde L.E.; Flinn I.; Gregory G.P.; Kim W.S.; Hess G.; El-Sharkawi D.; Diefenbach C.S.; Huang H.; To I.; Parreira J.; Wu M.; Kwan A.; Assouline S. | |
| 5-Aug-2021 | Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. | Assouline S.E.; Kim W.S.; Sehn L.H.; Schuster S.J.; Cheah C.Y.; Nastoupil L.J.; Shadman M.; Yoon S.-S.; Matasar M.J.; Diefenbach C.; Gregory G.P.; Bartlett N.L.; Wei M.C.; Doral M.Y.; Yin S.; Negricea R.; Li C.-C.; Penuel E.M.; Huang H.; Budde L.E. | |
| 13-Aug-2019 | An ongoing phase 1/1b trial investigating novel treatment regimens with mosunetuzumab in relapsed/refractory B-cell nonhodgkin lymphoma. | Yoon S.; Kwan A.; Li C.C.; Sison I.; Wei M.C.; Yin S.; Yousefi K.; Kim W.S.; Assouline S.; Bartlett N.L.; Bosch F.; Budde L.E.; Cheah C.; Gregory G.P.; Hong J.; Ku M.; Marlton P.; Matasar M.; Nastoupil L.; Panizo C.; Sehn L.H.; Tzachanis D.; Chu W.; Hernandez M.G. | |
| 23-Nov-2023 | Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies. | Hernandez G.H.; So J.; Logronio K.A.; Kotturi M.F.; Kim W.S.; Armand P.; Cheah C.Y.; Gopal A.K.; Flinn I.W.; Gregory G.P.; Matasar M.J.; Nastoupil L.J.; Diefenbach C.S.; Yoon S.-S.; Ku M.; Qazi I.; Leabman M.K.; Sison I.; Keyt B.A.; Takimoto C.H.; Manley T.J.; Budde E.L. | |
| 25-Jan-2018 | Safety and activity of the highly specific BTK inhibitor bgb-3111 in patients with indolent and aggressive non hodgkin's lymphoma. | Tam C.S.; Lee W.-S.; Marlton P.; Gottlieb D.; Wang L. ; Huang J.; Hilger J.; Xue L.; Ro S.; Munoz J.; Johnston P.B.; Cull G.; Wang M.; Simpson D.; Kim W.S.; Opat S. | |
| 17-Dec-2021 | Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. | Tam C.S.; Opat S. ; Simpson D.; Cull G.; Munoz J.; Phillips T.J.; Kim W.S.; Rule S.; Atwal S.K.; Wei R.; Novotny W.; Huang J.; Wang M.; Trotman J. |